Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
22)15(14)24/h1-5
MDOTS profiling effectively recapitulates the in vivo response to PD-1 blockade +/− TBK1/IKKε inhibition
Smiles: C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)COCCCOCCNC(=O)C[C@@H]1N=C(C2=C(SC(C)=C2C)N2C1=NN=C2C)C1C=CC(C)=CC=1)C(C)(C)C)C1C=CC(=CC=1)C1SC=NC=1C
Combination with radiation
Science Translational Medicine
Saxagliptin in HCl 22)15(14)24/h1-5Saxagliptin, also known as BMS 477118, is a new oral hypoglycemic (anti diabetic drug) of the new dipeptidyl peptidase 4 (DPP 4) inhibitor class of drugs. Saxagliptin was approved in 2008 for the treatment of type 2 diabetes. Saxagliptin is a competitive DPP4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose
US$ 575.00
US$ 700.00
US$ 625.00
US$ 575.00
US$ 575.00